Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Inventiva ( (IVA) ) has issued an update.
Inventiva S.A. has announced a significant capital increase through the issuance of new ordinary shares and pre-funded warrants, amounting to a total of €115,565,430.37. This strategic financial move is aimed at enhancing the company’s funding capabilities, potentially strengthening its position in the pharmaceutical sector by increasing its capacity to invest in research and development, thus benefiting stakeholders and supporting its long-term growth objectives.
More about Inventiva
Inventiva S.A. operates in the pharmaceutical industry and is headquartered in France. The company is involved in the research and development of small molecule therapies for the treatment of fibrotic, cancer, and other diseases, focusing on innovative solutions for unmet medical needs.
YTD Price Performance: -45.75%
Average Trading Volume: 214,400
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $210.2M
See more insights into IVA stock on TipRanks’ Stock Analysis page.
